Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
Angiogenesis and activation of the epidermal growth factor (EGFR) pathway play an essential role in tumor proliferation and metastasis. Targeting angiogenesis or EGFR alone does not yield adequate tumor contro...Experimental Hematology & Oncology 2020 9:7Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysis
The efficacy and safety of rituximab (RTX) on hemolytic anemia (HA) is unknown. Therefore we retrospectively analyze the efficacy and safety of RTX in autoimmune hemolytic anemia (AIHA) and microangiopathic he...Experimental Hematology & Oncology 2020 9:6Alternative donor peripheral blood stem cell transplantation for the treatment of high-risk refractory and/or relapsed childhood acute leukemia: a randomized trial
The high-risk refractory and/or relapsed (R/R) childhood acute leukemia prognosis is poor, and allogeneic stem cell transplantation (allo-HSCT) is the most prudent treatment modality. However, there are limite...Experimental Hematology & Oncology 2020 9:5Clinical implications of recurrent gene mutations in acute myeloid leukemia
Acute myeloid leukemia (AML) is a genetically heterogeneous clonal malignancy characterized by recurrent gene mutations. Genomic heterogeneity, patients’ individual variability, and recurrent gene mutations ar...Experimental Hematology & Oncology 2020 9:4Indirect comparison of azacitidine and decitabine for the therapy of elderly patients with acute myeloid leukemia: a systematic review and network meta-analysis
The DNA hypomethylating agents (HMAs) decitabine and azacitidine have been widely used in the management of elderly patients with acute myeloid leukemia (AML). However, no direct clinical trials have been carr...Experimental Hematology & Oncology 2020 9:3Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia
In this study, we retrospectively summarized the differences of molecular gene mutations between MDS and AML patients, as well as the young and older age groups of MDS and AML patients. We also analyzed the re...Experimental Hematology & Oncology 2020 9:2The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells
Evasion from programmed cell death is a hallmark of cancer and can be achieved in cancer cells by overexpression of inhibitor of apoptosis proteins (IAPs). Second mitochondria-derived activator of caspases (SM...Experimental Hematology & Oncology 2020 9:1Immune pressures drive the promoter hypermethylation of neoantigen genes
Cancer cells with strong immunogenicity are susceptible for elimination by cancer immunoediting, while the subpopulations with weak immunogenicity survive. As a result, a subset of cancer cells evade the immun...Experimental Hematology & Oncology 2019 8:32The Article to this article has been published in Nature 2019 567:1032Gut microbiome and CAR-T therapy
Considerable progress has been made in cancer therapeutics recently with targeted strategies that are efficacious and less toxic. Immunotherapy and chimeric antigen receptor (CAR) T-cells are increasingly bein...Experimental Hematology & Oncology 2019 8:31A high-throughput screening identifies histone deacetylase inhibitors as therapeutic agents against medulloblastoma
Medulloblastoma is the most frequently occurring malignant brain tumor in children. Current treatment strategies for medulloblastoma include aggressive surgery, cranio-spinal irradiation and adjuvant chemother...Experimental Hematology & Oncology 2019 8:30Advances and perspectives of PARP inhibitors
DNA damage repair deficiency leads to the increased risk of genome instability and oncogenic transformation. In the meanwhile, this deficiency could be exploited for cancer treatment by inducing excessive geno...Experimental Hematology & Oncology 2019 8:29Recent advances on blinatumomab for acute lymphoblastic leukemia
Although complete remission rate of B cell acute lymphoblastic leukemia (B-ALL) has improved significantly over the past few decades, patients with relapsed/refractory ALL still have dismal outcome. Tyrosine k...Experimental Hematology & Oncology 2019 8:28Development of molecular and pharmacological switches for chimeric antigen receptor T cells
The use of chimeric antigen receptor (CAR) T cell technology as a therapeutic strategy for the treatment blood-born human cancers has delivered outstanding clinical efficacy. However, this treatment modality c...Experimental Hematology & Oncology 2019 8:27The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis
Recently, a series of clinical trials showed that combination of anti-programmed cell death-1 (α-PD-1) and anti-cytotoxic T-lymphocyte-associated protein 4 (α-CTLA-4) could effectively eliminate tumor. However...Experimental Hematology & Oncology 2019 8:26Targeted and novel therapy in advanced gastric cancer
The systemic treatment options for advanced gastric cancer (GC) have evolved rapidly in recent years. We have reviewed the recent data of clinical trial incorporating targeted agents, including inhibitors of a...Experimental Hematology & Oncology 2019 8:25Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort
Cell-free DNA (cfDNA) next-generation sequencing has the potential to capture tumor heterogeneity and genomic evolution under treatment pressure in a non-invasive manner. Here, we report the detection of EGFR L79...Experimental Hematology & Oncology 2019 8:24LY86, LRG1 and PDE9A genes overexpression in umbilical cord blood hematopoietic stem progenitor cells by acute myeloid leukemia (M3) microvesicles
Microvesicles as a new device of cell–cell communication are potentially able to induce some phenotypes and genotypes of an origin cell in a target cell. We evaluate the role of leukemia microvesicles on the l...Experimental Hematology & Oncology 2019 8:23Cabozantinib and apixaban: an hitherto unreported interaction
The use of direct oral anticoagulant in cancer patients is an emerging issue, which seems to be an alternative to low molecular weight heparin. Every year several new drugs are approved as anticancer treatment...Experimental Hematology & Oncology 2019 8:22Role of some members of chemokine/cytokine network in the pathogenesis of thalassemia and sickle cell hemoglobinopathies: a mini review
The word of hemoglobinopathy is described for an array of disorders that affecting hemoglobin (Hb) functions. Hb is a molecule with 68 kDa molecular weight, serving as oxygen carrying metalloprotein. Hemoglobi...Experimental Hematology & Oncology 2019 8:21Autoimmune rhabdomyolysis and a multiorgan display of PD-1 inhibitor induced immune related adverse events during treatment of metastatic melanoma
Programmed death-1 (PD-1) inhibitors are among the immunotherapies that have revolutionized our approach to treating several cancers. These novel agents act by blocking PD-1 receptor/PD-1 ligand interactions t...Experimental Hematology & Oncology 2019 8:20Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
Non-small cell lung cancer (NSCLC) has been threatening human health for years. Cytotoxicity-based chemotherapy seems to reach plateau in NSCLC treatment. Immunotherapy with immune checkpoint inhibitors (ICIs)...Experimental Hematology & Oncology 2019 8:19A novel RNA variant of human concentrative nucleoside transporter 1 (hCNT1) that is a potential cancer biomarker
The human concentrative nucleoside transporter 1 (hCNT1) a product of the SLC28A1 gene is one of the three concentrative nucleoside transporters, with a substrate specificity for physiological pyrimidine nucleosi...Experimental Hematology & Oncology 2019 8:18Analysis of TET2 mutations in paroxysmal nocturnal hemoglobinuria (PNH)
Large clonal populations of cells bearing PIG-A mutations are the sine qua non of PNH, but the PIG-A mutation itself is insufficient for clonal expansion. The association between PNH and aplastic anemia supports ...Experimental Hematology & Oncology 2019 8:17Frontline therapies for untreated chronic lymphoid leukemia
Therapy for chronic myeloid leukemia (CLL) is going through a major paradigm shift. Combination chemoimmunotherapy regimens have been the frontline therapies for CLL, whereas chlorambucil remained the standard...Experimental Hematology & Oncology 2019 8:15Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
The Bruton’s Tyrosine Kinase (BTK)-inhibitor ibrutinib is highly active in mantle cell lymphoma (MCL) but may inhibit response to anti-CD20 antibody as previously shown in CLL models. We investigated how antib...Experimental Hematology & Oncology 2019 8:16Healthcare cost comparison analysis of nivolumab in combination with ipilimumab versus nivolumab monotherapy and ipilimumab monotherapy in advanced melanoma
Monoclonal antibodies targeting the cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) (e.g., ipilimumab [IPI]) and the programmed cell death-1 (PD1) receptor (e.g., nivolumab [NIVO]) represent significant br...Experimental Hematology & Oncology 2019 8:14An expanded biomarker panel for the detection of prostate cancer from urine DNA
Prostate cancer diagnosis using the PSA test remains controversial because of overdiagnosis and overtreatment of potentially indolent cancers. There remains a need to increase the diagnostic lead time and to t...Experimental Hematology & Oncology 2019 8:13Novel GTF2I–PDGFRB and IKZF1–TYW1 fusions in pediatric leukemia with normal karyotype
Many cases of acute lymphoblastic leukemia (ALL) carry visible acquired chromosomal changes of pathogenetic, diagnostic, and prognostic importance. Nevertheless, from one-fourth to half of newly diagnosed ALL ...Experimental Hematology & Oncology 2019 8:12NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children
Hepatoblastoma is the most common hepatic malignancy in children, accounting for approximately 80% of all childhood liver tumors. KRAS and NRAS, members of the RAS gene family, are closely linked to tumorigenesis...Experimental Hematology & Oncology 2019 8:11Development of a high resolution melting analysis assay for rapid identification of JAK2 V617F missense mutation and its validation
Myeloproliferative neoplasms (MPN) are heterogeneous diseases that classified by the presence of Philadelphia chromosome into Philadelphia chromosome negative (Ph-neg) and positive (Ph-pos) myeloproliferative ...Experimental Hematology & Oncology 2019 8:10Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose
Patients with Myelodysplastic Syndromes (MDS) and secondary Acute Myeloid Leukemia (sAML) have a very poor prognosis after failure of hypomethylating agents (HMA). Stem cell transplantation is the only effecti...Experimental Hematology & Oncology 2019 8:9Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation
Immune checkpoint inhibitors have radically changed the landscape of anti-tumor therapies in several malignancies. However the adverse events associated with immune checkpoint blockade in combination with othe...Experimental Hematology & Oncology 2019 8:8The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994–2016
Autologous stem-cell transplantation (ASCT) is a common treatment for lymphoma but it has some mortality.Experimental Hematology & Oncology 2019 8:7Thyroid dysfunction from inhibitor of fibroblast growth factor receptor
Thyroid dysfunction has not been previously reported in clinical trials of selective fibroblast growth factor receptor (FGFR) inhibitors including AZD4547. Herein, we report a case of worsening hypothyroidism ...Experimental Hematology & Oncology 2019 8:6Immunotherapy in extensive small cell lung cancer
Small cell lung cancer which constitutes about 15% of lung cancers is pathobiologically and clinically distinct from non small cell cancer. Histologically it is characterized by small cells with scant cytoplas...Experimental Hematology & Oncology 2019 8:5Bortezomib-induced hyponatremia: tolvaptan therapy permits continuation of lenalidomide, bortezomib and dexamethasone therapy in relapsed myeloma
The development of hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) is well recognised in multiple myeloma (MM). SIADH, due to either MM or Bortezomib can be hazardous as se...Experimental Hematology & Oncology 2019 8:4Cytogenetics and FLT3-ITD mutation predict clinical outcomes in non transplant patients with acute myeloid leukemia
Cytogenetic abnormalities and mutated genes indicate the role of consolidation therapy with hematopoietic stem cell transplantation (HSCT) or chemotherapy in acute myeloid leukemia (AML). In this study, we con...Experimental Hematology & Oncology 2019 8:3Mantle cell lymphoma and its management: where are we now?
Mantle cell lymphoma is a relatively new recognized hematological malignant disease, comprising of 2.5–6% non-Hodgkin’s lymphomas. The complexity of its clinical presentations (nodular pattern, diffuse pattern...Experimental Hematology & Oncology 2019 8:2Outcomes following second allogeneic stem cell transplant for disease relapse after T cell depleted transplant correlate with remission status and remission duration after the first transplant
Second allogeneic hematopoietic stem cell transplant (HCT) remains as an option for disease relapse after initial HCT.Experimental Hematology & Oncology 2019 8:1Methylome of human senescent hematopoietic progenitors
Senescence, a state of permanent cell cycle arrest, can be induced by DNA damage. This process, which was initially described in fibroblasts, is now recognized to occur in stem cells. It has been well characte...Experimental Hematology & Oncology 2018 7:32The epidemiology and clinical characteristics of myeloproliferative neoplasms in Malaysia
The evolution of molecular studies in myeloproliferative neoplasms (MPN) has enlightened us the understanding of this complex disease consisting of polycythaemia vera (PV), essential thrombocythemia (ET) and p...Experimental Hematology & Oncology 2018 7:31Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine
Organoid technology bridges the gap between conventional two-dimensional cell line culture and in vivo models. The near-physiological technology can virtually recapitulates organ development and human diseases...Experimental Hematology & Oncology 2018 7:30Early vs. late MRD response- and risk-based treatment intensification of childhood acute lymphoblastic leukemia: a prospective pilot study from Saudi Arabia
Refinement of risk-based treatment stratification by minimal residual disease (MRD) at different time points has improved outcomes of childhood acute lymphoblastic leukemia (ALL). In this prospective study we ...Experimental Hematology & Oncology 2018 7:29The role of neoantigen in immune checkpoint blockade therapy
Immune checkpoint inhibitor induces tumor rejection by activated host immune system. The anti-tumor immune response consists of capture, presentation, recognition of neoantigen, as well as subsequent killing o...Experimental Hematology & Oncology 2018 7:28Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth
The monoclonal antibody daratumumab, approved for treating myeloma, targets CD38, a protein on myeloma and also on CD34+ hematopoietic progenitor cells. Because mobilized CD34+ cells are critical for stem cell...Experimental Hematology & Oncology 2018 7:27Early detection of transformation to BPDCN in a patient with MDS
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by neoplastic cells that are positive for CD123, CD4, BDCA2, and TCL1 and aberrant expression ...Experimental Hematology & Oncology 2018 7:26Induction of anti-leukemic responses by stimulation of leukemic CD3+ cells with allogeneic stimulator cells
Immunotherapeutic protocols have focused on identification of stimuli that induce effective anti-leukemic immune responses. One potent immune stimulus is the encounter with allogeneic cells. Our group previous...Experimental Hematology & Oncology 2018 7:25
No hay comentarios:
Publicar un comentario